Surgical & Medical Instruments & Apparatus · SIC 3841

Nuo Therapeutics, Inc.

AURX

Watch

Latest revenue

$1.3M

as of 2026-03-31

Latest net income

$-618.5K

as of 2026-03-31

Net margin

-47.5%

as of 2026-03-31

4.7
of 10

ActaClear Score

Neutral
#105 of 138 in Surgical & Medical Instruments & Apparatus
+0.1 · 2d
Profitability·25%
4.7
Growth·15%
Value·20%
2.5
Quality·20%
6.6
Momentum·20%
5.2

Computed from 5 years of SEC fundamentals + latest market data, ranked within Surgical & Medical Instruments & Apparatus (138 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.

Community sentiment

Where do you think AURX is heading?

1 month
6 months
12 months
5 years
Sign in free to vote and see community sentiment

Price · 5Y

+4.1% / yr 15.6 pts / yr vs S&P 500 17.2% total
Compare:

Live market

delayed ≤15 min
$1.16
9.43%
Market cap
$56.2M
Enterprise value
$56.9M
P/E (trailing)
Forward P/E
P/B
Dividend yield
0.0%
52-wk high
$3.23
52-wk low
$0.84
Beta
Shares out
48.4M

5-year trend

What this company does

AI

ITEM 1. Business Corporate Overview Nuo Therapeutics, Inc. is a Delaware corporation organized in 1998 under the name Informatix Holdings, Inc. In 1999, Autologous Wound Therapy, Inc., an Arkansas Corporation, merged with and into Informatix Holdings, Inc. and the name of the surviving corporation was changed to Autologous Wound Therapy, Inc. In 2000, Autologous Wound Therapy, Inc. changed its name to Cytomedix, Inc. (“Cytomedix”). In 2001, Cytomedix, filed for bankruptcy, from which it emerged in 2002 under a Plan of Reorganization. In September 2007, Cytomedix received Section 510(k) clearance from the U. S. Food and Drug Administration (“FDA”) for the AutoloGel™ System, now known as the…

AI summary unavailable — showing raw filing excerpt

Generated from AURX's filing dated 2026-03-30

Key risks

AI

ITEM 1A. Risk Factors An investment in the Company involves a high degree of risk. Before making an investment decision with respect to our common stock, you should consider the risks described below in addition to the cautionary statements and risks described elsewhere and the other information in this Annual Report and in our other filings with the SEC, including subsequent reports on Forms 10-Q and 8-K. The risks described below may not be the only risks the Company faces. Additional risks not yet known or currently believed to be immaterial may also impair our business. If any of these known or unknown risks or uncertainties actually occurs, our business, financial condition or results…

AI summary unavailable — showing raw filing excerpt

Generated from AURX's filing dated 2026-03-30

Profitability

Gross margin

66.9%

14.0%

Operating margin

-76.0%

57.8%

Net margin

-75.8%

55.5%

Return on equity

-489.0%

8.1%

Return on assets

-136.1%

30.3%

Leverage

Debt / equity

2.59×

97.1%

Long-term debt / equity

0.97×

Debt / assets

72.2%

27.0%

Earnings tracker

QuarterRevenueYoYNet incomeYoYNet margin

Q1 2026

2026-03-31

$1.3M+168.8%$-618.5K+17.1%-47.5%

Q4 2025

2025-12-31

$1.1M+177.8%$-578.5K-16.5%-52.7%

Q3 2025

2025-09-30

$1.0M+178.2%$-537.9K+7.0%-52.1%

Q2 2025

2025-06-30

$700.2K+92.0%$-649.7K-20.3%-92.8%

Q1 2025

2025-03-31

$484.4K+106.5%$-746.1K-5.3%-154.0%

Q4 2024

2024-12-31

$394.9K$-496.7K-125.8%

Q3 2024

2024-09-30

$371.0K+59.7%$-578.2K+26.9%-155.9%

Q2 2024

2024-06-30

$364.8K+208.7%$-540.1K+38.1%-148.1%

Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.

Industry trend

Surgical & Medical Instruments & Apparatus · SIC 3841

No data yet for industry average

Your notes

Keep private notes on AURX — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

Insider buying

$200.0K

Insider selling

$300.0K

Net activity

−$100.0K

Distinct insiders

2

Open-market trades over the last 365 days.

Recent transactions

DateInsiderTypeSharesPriceValue
2025-11-28

David Emerson Jorden

CEO/CFO

Sale200,000$1.50$300.0K
2025-07-30

Charles E Sheedy

10%+ owner

Purchase133,333$1.50$200.0K

Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.

Who owns AURX

No institutional holdings on file for AURX yet.

Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).

Top questions investors are asking

Coming once AURX's latest filing finishes processing.

Investor sentiment
No votes yet
0 this week · 0 total

Sign in to vote. Votes use 7-day half-life decay.

What matters about AURX?
Tap any that apply. Aggregates show what other investors flag.

Sign in to tap. 7-day half-life decay.

Latest filing impact
After reading, did this filing make you: